REVIEW ARTICLE

Mutations Driving Breast Cancer: A Comprehensive Review of Genetic Alterations

P. Dharani Prasad, Kamati Mounika, C. Praneeth Babu, B. Rushitha, A. S. Sri Hari, E. Indraja, M. Ruchitha, C. Jyothi

Department of Pharmacy Practice, MB School of Pharmaceutical Sciences, Mohan Babu University (Erstwhile: Sree Vidyanikethan College of Pharmacy), Tirupati, Andhra Pradesh, India

Abstract

The abstract of the paper on gene mutations in breast cancer presents several key points regarding the disease's significance and underlying genetic mechanisms: Breast cancer is identified as a major public health issue and a leading cause of cancer-related deaths among women globally. This highlights the urgency of addressing the disease through research and treatment strategies. The paper notes that various genes and their mutations have been linked to breast cancer. Despite the complexity of the disease, advancements in research techniques have allowed for the identification of these genetic factors, which are crucial for understanding breast cancer's etiology. The development of breast cancer is described as a multifaceted process influenced by hormonal, dietary, and genetic components. This complexity necessitates a comprehensive approach to prevention and treatment.

Key words: Breast cancer, gene mutations, hormonal changes

INTRODUCTION

Breast cancer has become a severe public health concern and one of the leading causes of cancer-related death in women worldwide. Several genes and mutations in these genes linked to breast cancer have been identified using sophisticated techniques, despite the fact that the exact cause of breast cancer is still unknown.[1]

Breast cancer remains one of the most prevalent cancers affecting individuals worldwide. Understanding the genetic mechanisms that contribute to its development is crucial for improving diagnosis and treatment breast cancer development is a complex process influenced by various factors, including hormonal, dietary, and genetic components. Understanding these mechanisms is crucial for prevention and treatment strategies. The following sections outline key aspects of breast cancer development.

Hormonal influence

Breast cancer primarily originates in the terminal ductal lobular units (TDLUs) of the mammary gland, where estrogen plays a significant role in cell proliferation and carcinogenesis.[2,3]

Early exposure to estrogen, particularly during puberty, increases susceptibility to cancer, while full-term pregnancies can reduce this risk by promoting the differentiation of breast cells.[4]

Dietary factors

Diet significantly impacts breast cancer risk; high consumption of red meat and processed foods correlates with increased risk, while diets rich in fruits, vegetables, and fish appear protective.[5]

Obesity, often linked to poor dietary choices, exacerbates cancer risk post-menopause due to increased estrogen levels.

Pre-neoplastic lesions

Certain lesions in the breast are pre-cursors to cancer, with a higher likelihood of malignancy compared to normal tissue.

Address for correspondence:
Kamati Mounika, Department of Pharmacy Practice, MB School of Pharmaceutical Sciences, Mohan Babu University (Erstwhile: Sree Vidyanikethan College of Pharmacy), Tirupati, Andhra Pradesh, India.
E-mail: kamatimounika04@gmail.com

Received: 07-10-2024
Revised: 12-12-2024
Accepted: 20-12-2024



Figure 1: Diagrammatic representation of the development of breast cancer

The presence of these lesions necessitates careful monitoring and intervention.

While significant progress has been made in understanding breast cancer development, ongoing research is essential to unravel the intricate interplay of these factors and improve prevention strategies.[6]

Understanding the development of breast cancer

Breast cancer develops through a series of complex biological changes, often beginning with pre-neoplastic conditions and it was shown in Figure 1. Here are the key points regarding how breast cancer develops:

Pre-neoplastic lesions

Certain focal lesions in the TDLU of the breast are considered pre-cancerous. These lesions have a higher probability of developing into cancer compared to normal tissue. The recognition of these pre-neoplastic tissues is crucial for understanding breast cancer development.

Pathological conditions

Pre-neoplasia is a pathological state that indicates a significant risk of malignancy morphological changes: The development of breast cancer can be traced through a morphological continuum, where normal cells transition to pre-neoplastic cells and eventually to cancerous cells.

This continuum includes various hyperplastic forms of epithelial cells that can lead to carcinoma *in situ*, a non-invasive form of cancer.

Age and hormonal influence

The occurrence of pre-neoplastic lesions increases with age and persists even after menopause. This suggests that hormonal changes may play a role in the development of these lesions, which are more prevalent in cancer-associated breasts compared to those from random autopsies.

Experimental evidence

While there is strong circumstantial evidence linking certain lesions to breast cancer, direct experimental proof is still lacking. Research indicates that hyperplastic lesions in the TDLU are common pre-cursors to breast cancer, but further studies are needed to confirm their pre-cancerous nature while genetic mutations are critical in understanding breast cancer, environmental factors, and lifestyle choices also significantly influence incidence rates, suggesting a multifactorial etiology.

Fibrocystic disease

This condition, characterized by hormonal imbalances leading to various alterations in breast tissue, is often associated with pre-neoplastic changes. It frequently involves multiple lesions and is linked to an increased risk of developing breast cancer.

Breast cancer is a significant global health issue, with genetic mutations playing a crucial role in its incidence. The most common mutations associated with breast cancer include those in the BRCA1 and BRCA2 genes, which are linked to hereditary cases and account for 5–10% of all breast cancer cases.[7]

Other notable genes include TP53, which is associated with triple-negative breast cancer, and moderate penetrance genes such as PALB2, ATM, and CHEK2.[8]

Impact of gene mutations on incidence rates

- High penetrance genes: Mutations in BRCA1 and BRCA2 significantly elevate breast cancer risk, leading to earlier onset and it was shown in Figure 2
- Moderate penetrance genes: Genes, such as CTLA-4 and Pik3ca contribute to a broader spectrum of breast cancer cases, affecting global incidence rates
- Emerging mutations: Recent studies highlight the role of MYC and cyclin E1 mutations, which may disrupt cell cycle regulation and contribute to tumorigenesis.[9]

MUTATIONS INDUCED BREAST CANCER

- Breast cancer is significantly influenced by key genetic mutations that drive tumorigenesis. Notably, mutations in HER2 and PIK3CA are prevalent, often co-occurring, and leading to aggressive cancer phenotypes.



Figure 2: Mutations incidence rate as per blood pressure per year

Key genetic mutations

- HER2 V777L and PIK3CA H1047R: These mutations activate the p21-CDK4/6-Cyclin D1 axis, promoting tumor growth and drug resistance. Approximately 40% of HER2-mutated breast cancers also exhibit PIK3CA mutations, resulting in accelerated tumor formation and increased invasiveness.[10]
- Somatic mutations in normal tissue: Young women with a high familial risk of breast cancer often harbor somatic mutations in adjacent normal breast tissue, which may contribute to early-onset tumorigenesis.
- These mutations predominantly involve single nucleotide variants, particularly in zinc finger proteins, which are linked to cancer progression.

TNFa and ZEB1: In chemo-resistant breast cancer cells, the upregulation of TNFa and ZEB1 promotes epithelial-mesenchymal transition, enhancing invasiveness and resistance to treatment.[11]

- BRCA1 and BRCA2 gene mutations: Significantly influence breast cancer development and progression, primarily by acting as tumor suppressor genes. These mutations are responsible for a substantial proportion of hereditary breast cancer cases, with BRCA1 and BRCA2 mutations accounting for over 90% of hereditary instances.

The mutations lead to genomic instability, increasing the likelihood of tumorigenesis due to defects in DNA repair mechanisms.[12]

- Tumors associated with BRCA1 mutations often exhibit more aggressive characteristics, potentially leading to poorer outcomes.[13]
- Genetic testing for these mutations is crucial for risk assessment and management, although the clinical significance of some mutations remains.[14]

Despite the established link between BRCA mutations and breast cancer, the exact mechanisms by which these mutations influence tumor behavior and treatment responses are still under investigation, highlighting the complexity of cancer genetics.

EARLY-STAGE SYMPTOMS

The early-stage symptoms of breast cancer in individuals with gene mutations, particularly those involving BRCA1, BRCA2, and PALB2, often manifest as a combination of physical and psychological challenges. Understanding these symptoms is crucial for early detection and intervention and it was shown in Figure 3.



Figure 3: Anatomy of breast

Common physical symptoms

Lump or mass: The most prevalent early symptom is the presence of a lump in the breast, often detected during self-examination or routine screening.[15]

Pain: Many patients report localized pain, which can be associated with tumor growth or inflammation.[16]

Fatigue: This symptom is frequently noted and can be exacerbated by treatment-related factors.[17]

Psychological symptoms

- Anxiety and depression: Genetic pre-dispositions can lead to heightened susceptibility to psychological symptoms, impacting the overall quality of life.[16]
- Cognitive impairment: Some individuals experience difficulties with memory and concentration, often linked to both the cancer and its treatment. While these symptoms are common, individual experiences can vary significantly based on genetic factors and tumor characteristics, highlighting the need for personalized approaches in management and treatment.

PRECAUTIONS

To effectively prevent gene mutations in breast cancer, particularly among high-risk individuals, several strategies can be employed. These include both surgical and non-surgical interventions that target genetic pre-dispositions, particularly in BRCA mutation carriers.

Surgical interventions

- Prophylactic surgeries: Procedures such as bilateral mastectomy and sapling-oophorectomy significantly reduce cancer risk in mutation carriers. Studies show that these surgeries can lead to a disease-free survival rate, with no recurrence observed in patients who underwent prophylactic mastectomy.[18]
- Uptake variability: The decision to undergo these surgeries is influenced by personal history and socioeconomic factors, with a notable percentage of patients opting for these interventions when they have a prior breast cancer diagnosis.[19]

Non-surgical strategies

- Chemoprevention: Endocrine treatments, such as tamoxifen and aromatase inhibitors have shown effectiveness in secondary prevention, although their primary prevention efficacy remains unproven.[20]
- Intraductal chemotherapy: Innovative approaches, such as intraductal administration of chemotherapeutics, have demonstrated promise in pre-clinical studies, targeting the mammary epithelial tissue directly.[21]

While surgical options are highly effective, they carry significant psychological and physical implications. Therefore, ongoing research into less invasive alternatives is crucial for comprehensive breast cancer prevention strategies.

TREATMENT STRATEGIES

The treatment strategies for gene-mutated breast cancer have evolved significantly, focusing on targeted therapies and innovative approaches, such as gene therapy. These strategies aim to exploit specific genetic mutations to improve patient outcomes.

Targeted therapies

- PARP inhibitors: Particularly effective for BRCA1/2 mutations, these agents exploit DNA repair deficiencies, leading to enhanced tumor cell death.[22]
- Chemotherapy combinations: In triple-negative breast cancer, combinations of taxanes and platinum agents have shown efficacy, especially in BRCA1 mutation carriers.[23]
- Mutation-specific treatments: Targeted therapies based on specific mutations (e.g., PIK3CA, TP53) have been linked to variable prognoses, necessitating personalized treatment plans.

Gene therapy approaches

- Innovative modalities: Gene therapy strategies, including mutation compensation and antiangiogenic therapies, are being explored to enhance treatment efficacy and reduce resistance.[24]

While these strategies show promise, challenges remain in optimizing treatment based on individual genetic profiles,

highlighting the need for ongoing research and clinical trials to refine these approaches.

CONCLUSION

The conclusion of the paper on gene mutations in breast cancer emphasizes several important points regarding the understanding and management of the disease:

Importance of genetic research

The paper underscores the necessity of ongoing research into the genetic mutations associated with breast cancer. Identifying these mutations is crucial for developing targeted therapies and personalized treatment plans that can improve patient outcomes.

Role of preventive strategies

It highlights the significance of both surgical and non-surgical interventions in preventing breast cancer, particularly for individuals with known genetic pre-dispositions, such as BRCA mutation carriers. Prophylactic surgeries and chemoprevention strategies are noted as effective measures to reduce cancer risk.

Psychological considerations

The conclusion also addresses the psychological impact of breast cancer and its treatment on patients. It points out that genetic pre-dispositions can lead to increased anxiety and depression, which necessitates a holistic approach to patient care that includes mental health support.

REFERENCES

1. Taheri G, Habib M. Uncovering driver genes in breast cancer through an innovative machine learning mutational analysis method. Comput Biol Med 2024;171:108234.
2. Russo J, Russo IH. Cellular basis of breast cancer susceptibility. Oncol Res 1999;11:169-78.
3. Russo J, Tahin Q, Lareef MH, Hu YF, Russo IH. Neoplastic transformation of human breast epithelial cells by estrogens and chemical carcinogens. Environ Mol Mutagen 2002;39:254-63.
4. de Waard F, Trichopoulos D. A unifying concept of the aetiology of breast cancer. Int J Cancer 1988;41:666-9.
5. Ingram DM, Nottage E, Roberts T. The role of diet in the development of breast cancer: A case-control study of patients with breast cancer, benign epithelial hyperplasia and fibrocystic disease of the breast. Br J Cancer 1991;64:187-91.
6. Wellings SR. Development of human breast cancer. Adv Cancer Res 1980;31:287-314.
7. Ul Haq I, Alam N, Ali A, Khan S, Ali F, Lu H. Moderate spectrum genes associated with breast cancer. Am J Biomed Sci Res 2022;15:380-6.
8. Fairoosa P, Witharana C. Gene mutations in hereditary breast cancer- a review. Eur J Med Health Sci 2020;2:1-9.
9. Cheng X, Sun Y, Highkin M, Vemalapally N, Jin X, Zhou B, *et al*. Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6-cyclin D1 axis to drive tumorigenesis and drug resistance. Cancer Res 2023;83:2839-57.
10. Rozenblit M, Suwalska A, Hofstatter EW, Reisenbichler E, Harigopal M, Marczyk M, *et al*. Somatic mutations in tumour-adjacent normal breast tissue in young women with high risk family history. J Clin Oncol 2023;41:576.
11. Diaz JO, Silatcha AC, Cutter N. TNFa and ZEB1 contribute to tumorigenesis in chemo-resistant breast cancer cells. J Stud Res 2023;12:1-11.
12. Yang X, Lippman ME. BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat 1999;54:1-10.
13. Goodwin PJ, Phillips KA, West DW. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. New Engl J Med 2007;357:1555; author reply 1556.
14. Carter RF. BRCA1, BRCA2 and breast cancer: A concise clinical review. Clin Invest Med 2001;24:147-57.
15. Jeon JE, Chen KT, Madison R, Schrock AB, Sokol E, Levy MA, *et al*. HRD signature and HRD genomic landscape of tumours from 896 patients with early-stage breast cancer (BC). J Clin Oncol 2023;41:539.
16. Abubakar MA, Gan SH. Genetic polymorphisms associated with common symptoms experienced by breast cancer patients. Biomed Res 2018;29:1164-75.
17. Yang GS, Kumar S, Dorsey SG, Starkweather AR, Kelly DL, Lyon DE. Systematic review of genetic polymorphisms associated with psychoneurological symptoms in breast cancer survivors. Support Care Cancer 2019;27:351-71.
18. Tokocin M, Yigitbas H, Çelik A. Breast cancer treatment in genetic mutation carriers: Surgical treatment, prophylactic mastectomy. Atlas Univ Tip Saglik Bilimleri Derg 2023;10:1-7.
19. Shafaee MN, Brown R, Higashiyama N, Bulsara S, Garza G, Sullivan C, *et al*. Risk reducing surgeries among mutation carriers treated at a safety NET hospital breast cancer clinic. J Clin Oncol 2022;40:e12583.
20. Singer CF. Nonsurgical prevention strategies in BRCA1 and BRCA2 mutation carriers. Breast Care (Basel) 2021;16:144-8.
21. De Groot JS, van Diest PJ, Derksen PW. Prophylaxis of hereditary breast cancer. Aging (Albany NY) 2017;9:2453-4.
22. Rowe BP, Glazer PM. Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res 2010;12:203.
23. Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33.
24. Stoff-Khalili MA, Dall P, Curiel DT. Gene therapy for carcinoma of the breast. Cancer Gene Ther 2006;13:633-47.

Source of Support: Nil. **Conflicts of Interest:** None declared.